TITLE

Preliminary Randomized Open Labeled Comparative Analysis of Efficacy & Safety of Inhaled Tiotropium and Tiotropium Plus Formoterol in COPD

AUTHOR(S)
Pukhta, Muzaffer Ahmad; Ashai, Zubair Ahmad; Shah, Mushtaq Ahmad; Abbas, Zaffar; Farhat, Samina; Mir, Shakeel Ahmad; Singh, Z.; Tandon, Vishal R.
PUB. DATE
January 2010
SOURCE
JK Science;Jan-Mar2010, Vol. 12 Issue 1, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A randomized, open labeled comparative analysis for 2-week therapy of inhaled Tiotropium (T) (n=30) and Tiotropium plus Formoterol (TF) (n=30) once daily was carried in stable COPD patients. Objective parameters like lung functions (FEV1 and FVC), SBP, DBP, pulse and subjective parameters like improvement in respiratory symptoms & safety were assessed at baseline and after 2 weeks of treatment. Mean FEV1 was 1.0963±0.3826 & 1.1657±0.3701 as well as 1.1227±0.4129 & 1.2260±0.3830 before & after treatment with inhaled T & TF respectively. A statistically significant p<0.05 and p<0.001 improvement was only observed for FEV1 without significantly affecting other study parameters with two treatment modalities respectively when analyzed from respective base lines. However, on comparing the post drug improvement in objective & subjective parameters among T & TF treatment arms showed statistically insignificant p>0.05 variation. Both the regimens were well tolerated and no case warranted withdrawal of treatment. The present study suggests that in the treatment of COPD, inhaled long acting bronchodilators (T & TF) on comparison appear equally effective & safe.
ACCESSION #
51086848

 

Related Articles

  • Preliminary Randomized Open Labeled Comparative Analysis of Efficacy & Safety of Inhaled Tiotropium and Tiotropium Plus Formoterol in COPD. Pukhta, Muzaffer Ahmad; Ashai, Zubair Ahmad; Shah, Mushtaq Ahmad; Abbas, Zaffar; Farhat, Samina; Mir, Shakeel Ahmad; Singh, Z.; Tandon, Vishal R. // JK Science;Jan-Mar2010, Vol. 12 Issue 1, p27 

    A randomized, open labeled comparative analysis for 2-week therapy of inhaled Tiotropium (T) (n=30) and Tiotropium plus Formoterol (TF) (n=30) once daily was carried in stable COPD patients. Objective parameters like lung functions (FEV1 and FVC), SBP, DBP, pulse and subjective parameters like...

  • Best Combination Therapy for Symptomatic Relief in COPD.  // OB/GYN Clinical Alert;Oct2008 Clinical Briefs in Primary, p20 

    The article focuses on a study that discovers the best combination therapy for symptomatic relief in chronic obstructive pulmonary disease (COPD). The study evaluates the patients with moderates COPD to receive six weeks of either tiotropium + formoterol or salmeterol + fluticasone. It was found...

  • Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Buhl, Roland; Gessner, Christian; Schuermann, Wolfgang; Foerster, Karin; Sieder, Christian; Hiltl, Simone; Korn, Stephanie // Thorax;Apr2015, Vol. 70 Issue 4, p311 

    Background: QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose...

  • Early tiotropium slows lung decline.  // Pulse;9/2/2009, Vol. 69 Issue 27, p11 

    The article reports on the effectiveness of tiotropium used for treating chronic obstructive pulmonary disease (COPD) in patients with early symptoms in slowing decline in lung function. A trial showed that patients with mild disease who had been excluded from previous trials responded to...

  • Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Mannino, David M.; Diaz-Guzman, Enrique; Buist, Sonia // Respiratory Research;Oct2011, Vol. 12 Issue 10, p1 

    Background: Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of postbronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung function available. We used pre-and post bronchodilator lung function data from...

  • Comparison of pre- and post-bronchodilator lung function as predictors of mortality: the Nord-Trøndelag Health Study (HUNT). Bhatta, Laxmi; Leivseth, Linda; Carslake, David; Langhammer, Arnulf; Xiao-Mei Mai; Yue Chen; Henriksen, Anne Hildur; Brumpton, Ben Michael // Norsk Epidemiologi;nov2018, Vol. 28 Issue Supplement 1, p41 

    Introduction: Post-bronchodilator lung function is recommended for the diagnosis of COPD. However, often only pre-bronchodilator lung function is available in clinical practice or in epidemiological studies. Aims: To investigate the discrimination ability of pre- and post-bronchodilator lung...

  • Long-Acting β-Agonists in the Treatment of Acute Exacerbations of COPD. Cazzola, M.; Matera, M.G.; D'Amato, M.; Noschese, P.; Califano, C.; Di Perna, F.; Terzano, C.; D'Amato, G. // Clinical Drug Investigation;2002, Vol. 22 Issue 6, p369 

    Objective: To evaluate the acute bronchodilating effect of cumulative doses of formoterol administered via TurbuhalerÅ’ or salmeterol administered via pressurised metered-dose inhaler (pMDI) in patients with mild acute exacerbations of chronic obstructive pulmonary disease (COPD) to determine...

  • Optimizing bronchodilation in COPD: double bronchodilator therapy. Beeh, Kai M.; Beier, Jutta // Hot Topics in Respiratory Medicine;2012, Vol. 7 Issue 21, p13 

    Bronchodilators are the cornerstone of symptomatic treatment for chronic obstructive pulmonary disease (COPD). They are recommended on a regular basis to prevent or reduce symptoms and exacerbations, with a preference for long-acting therapy rather than short-acting drugs. There are 2 classes of...

  • Long-term safety, eficacy, and patient acceptability of the tulobuterol patch. Ichikawa, Tomohiro; Sugiura, Hisatoshi // Research & Reports in Transdermal Drug Delivery;2013, Vol. 2, p9 

    The tulobuterol patch contains a β2-adrenergic agonist, is the first transdermal bronchodilator, and was developed in Japan. It relies on a matrix-type transdermal delivery system that contains both crystallized and molecular forms of tulobuterol. This delivery system enables the drug content...

  • Inhaled glycopyrronium bromide: first-line maintenance therapy for COPD. Suppli Ulrik, Charlotte // Hot Topics in Respiratory Medicine;2014, Vol. 9 Issue 27, p11 

    Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD), and several studies have demonstrated the clinical efficacy of long-acting muscarinic antagonists (LAMAs) for the treatment of COPD. Glycopyrronium bromide is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics